306768-95-6

Upstream product

• 306768-94-5 N-[4-(hydroxymethyl)phenyl]-N'-phenyl-urea 
• 623-04-1 4-aminobenzenemethanol 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 1179329-44-2 1-{4-[5,5-dimethyl-2,4-dioxo-3-(2-phenoxyphenyl)imidazolidin-1-ylmethyl]phenyl}-3-phenylurea 
• 1093659-17-6 1-(4-(3-phenylureido)-benzylamino)-9-fluoro-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 
• 306768-56-9 (3S)-(3,4-dimethoxyphenyl)-3-[(2S)-{2,4-dioxo-1-[4-(3-phenylureido)benzyl]-1,3-diazaspiro[4.5]dec-3-yl}-4-methylpentanoylamino]propionic acid 
• 306768-98-9 (2S)-{2,4-dioxo-1-[4-(3-phenylureido)benzyl]-1,3-diazaspiro[4.5]dec-3-yl}-4-methylpentanoic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps

Bacterial efflux pump systems contribute to antimicrobial resistance in pathogenic bacteria. The co-administration of bacterial efflux pump inhibitors with antibiotics is being pursued to overcome efflux-mediated resistance to antibiotics. In this study we investigated a strategy for converting broad-spectrum efflux pump substrates, fluoroquinolone antibacterial agents which are inherently recognized by most efflux transporters, into expanded spectrum efflux pump inhibitors. Employing this strategy against organisms expressing efflux pumps from the MFS, MATE and RND classes of pump systems, we report here the identification of an ofloxacin-based EPI that is a potent inhibitor of MFS (NorA) and MATE (MepA) efflux pumps in Staphylococcus aureus. The methods described here outline a process that we feel will be broadly applicable to the systematic identification of bacterial efflux pump inhibitors.

Aromatic β-amino acids as Asp-Phg mimics in LDV derived VLA-4 antagonists

Aromatic β-amino acid esters 2a-h were prepared in racemic and enantiomerically pure form by the Radionow reaction or based on the method described by Davis and used as mimics of the Asp-Phg C-terminus in LDV derived VLA-4 antagonists. As a promising β-am

Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom

The present invention relates to spiroimidazolidine derivatives of the formula I in which E, V, W, X, R1and R2have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, such as, for example, rheumatoid arthritis, or allergic disorders. The compounds of the formula I are also inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention also relates to processes for the preparation of the compounds of the formula I, pharmaceutical preparations which contain compounds of the formula I, and methods for treating these disorders.